Chesnara raises £140m towards HSBC Life acquisition

Deal valued at £260m

Cameron Roberts
clock • 1 min read

Life insurance and pensions consolidator, Chesnara, has raised £140 million via a Rights Issue of nearly 80 million new ordinary shares as it gears up to buy HSBC Life UK.

The new shares were priced at 176p per share, Chesnara received valid acceptances for just over 70 million new ordinary shares, or approximately 88% of the total shares issued. The amount raised will be used to aid in the consolidator's acquisition of insurer HSBC Life UK, according to Chesnara CEO Steve Murray. He said: "I am pleased to announce we have successfully raised gross proceeds of £140m to support the financing of our proposed acquisition of HSBC Life UK." For the remaining 12% of shares not under acceptance, RBS and ABN AMRO will be responsible for finding subscribers. ...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Companies

PFS' Carla Brown: 'We've built a stronger, more constructive relationship with the CII'

PFS' Carla Brown: 'We've built a stronger, more constructive relationship with the CII'

Professional body has ‘come through some challenging years’

Isabel Baxter
clock 13 November 2025 • 2 min read
WH Ireland confirms takeover approach from Team

WH Ireland confirms takeover approach from Team

10 December deadline

Sahar Nazir
clock 13 November 2025 • 1 min read
FNZ raises $650m in funding from institutional shareholders

FNZ raises $650m in funding from institutional shareholders

Aviva, Aberdeen, and Nucleus part of backing

Isabel Baxter
clock 12 November 2025 • 1 min read